Young patients with aortic valve disease face a uniquely difficult choice: no currently available prosthesis is ideal for a 25 or 40-year-old who may live another 40-60 years. Mechanical valves offer lifetime durability but impose lifelong warfarin anticoagulation with its attendant bleeding risks, dietary restrictions, and limitations during pregnancy. Bioprosthetic valves avoid anticoagulation but will fail within 10-20 years, guaranteeing one or more reoperations. The Ross procedure offers a third path. First performed by Donald Ross in 1967, it replaces the diseased aortic valve with the patient's own pulmonary valve (autograft) and implants a cadaveric pulmonary homograft in the pulmonary position. The autograft is a living tissue that grows, remodels, and resists degeneration — making it the only "replacement" that approaches the hemodynamic and biological properties of the native aortic valve. However, the Ross procedure converts a single-valve problem into a two-valve operation, carries a significant learning curve, and creates a dependency on pulmonary homograft availability and durability. It is one of the most debated and surgeon-dependent operations in cardiac surgery.
The Ross procedure excises the diseased aortic valve and replaces it with the patient's own pulmonary valve (autograft), which is then implanted in the aortic position. A cryopreserved pulmonary homograft (cadaveric donor valve) replaces the pulmonary valve. The autograft is living tissue with the potential for growth, self-repair, and resistance to calcification. Contemporary techniques use external reinforcement (Dacron or PTFE wrap) to prevent autograft root dilation.
Mechanical aortic valve replacement implants a bileaflet pyrolytic carbon prosthesis with lifetime structural durability. It is the most commonly performed aortic valve operation in young adults worldwide. Lifelong warfarin anticoagulation with target INR 2.0-3.0 is mandatory. The On-X mechanical valve may allow lower INR targets (1.5-2.0) based on the PROACT trial.
The 2020 ACC/AHA Guidelines list the Ross procedure as a reasonable alternative for young patients requiring aortic valve replacement when performed at experienced centers (Class IIb). The ESC 2021 Guidelines state the Ross procedure "may be considered in young adults when performed by experienced surgeons." Both sets of guidelines emphasize the requirement for dedicated surgical expertise and acknowledge the procedure's complexity. The relatively conservative guideline class reflects the limited number of surgeons and centers with adequate experience, rather than the quality of outcomes at experienced centers.
The Ross vs mechanical valve decision is profoundly impactful for young patients and benefits enormously from Heart Team input and, often, a second opinion. The cardiologist provides detailed echocardiographic assessment of the aortic root, pulmonary valve quality, and ventricular function. The surgeon evaluates Ross procedure feasibility based on root anatomy, bicuspid valve configuration, and their own expertise. WhiteGloveMD provides an unbiased assessment of whether the Ross procedure is appropriate and, critically, whether the patient should be referred to a dedicated Ross procedure center if their local surgeon lacks adequate experience.
The Ross procedure offers young patients the possibility of normal life expectancy without anticoagulation, with autograft function that approaches the native valve. However, it requires a fellowship-trained surgeon with dedicated Ross procedure expertise — this is not an operation that should be performed occasionally. Mechanical valves remain an excellent option with guaranteed durability, accepting the anticoagulation trade-off. The decision should involve careful discussion of lifestyle priorities, pregnancy planning, and access to a Ross-experienced surgeon.
Most experts recommend a minimum of 50-100 Ross procedures for proficiency, with ongoing annual volume of at least 10-20 per year. Ask your surgeon directly about their personal Ross procedure volume and outcomes. If your surgeon performs the Ross procedure only occasionally, consider seeking a referral to a dedicated center.
Yes — bicuspid aortic valve is actually the most common indication for the Ross procedure. The diseased bicuspid valve is replaced by the normal trileaflet pulmonary autograft. Results are excellent when performed by experienced surgeons. The key is ensuring the aortic root is not significantly dilated.
The pulmonary position operates at lower pressures than the aortic position, so the homograft lasts longer there (15-25 years). When it does fail, options include transcatheter pulmonary valve replacement (Melody or SAPIEN valve) or surgical re-replacement — a less complex operation than redo aortic surgery.
The Ross procedure is most beneficial for patients under 50, where the long anticoagulation-free interval has the greatest impact. Some centers perform the Ross procedure in select patients up to age 55-60 with good results. Above 60, the added complexity of the Ross is harder to justify when bioprosthetic options have adequate durability for the remaining life expectancy.
Our Heart Team evaluates your specific anatomy, risk factors, and goals to recommend the best approach. 48-hour turnaround.